Envoy Medical (NASDAQ:COCH) Shares Gap Down – Time to Sell?

Envoy Medical, Inc. (NASDAQ:COCH)’s share price gapped down prior to trading on Monday. The stock had previously closed at $5.9550, but opened at $5.11. Envoy Medical shares last traded at $6.56, with a volume of 23,099 shares changing hands.

Analysts Set New Price Targets

COCH has been the subject of several recent research reports. HC Wainwright restated a “buy” rating on shares of Envoy Medical in a report on Tuesday, October 13th. Loop Capital set a $20.00 target price on Envoy Medical in a research note on Monday, July 27th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Envoy Medical in a report on Monday, October 19th. Finally, Lake Street Capital began coverage on Envoy Medical in a research report on Tuesday, October 6th. They set a “buy” rating and a $25.00 price target for the company. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Envoy Medical currently has a consensus rating of “Hold” and an average target price of $21.67.

Envoy Medical Stock Up 9.4%

The business’s 50 day moving average price is $0.69 and its 200-day moving average price is $0.69. The company has a market cap of $502.89 million, a PE ratio of -8.41 and a beta of 1.97.

Envoy Medical (NASDAQ:COCH) last issued its earnings results on Monday, August 10th. The company reported ($0.70) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.10. The firm had revenue of $0.05 million during the quarter, compared to analyst estimates of $0.05 million. Equities analysts expect that Envoy Medical, Inc. will post -0.31 earnings per share for the current year.

Institutional Trading of Envoy Medical

An institutional investor recently bought a new position in Envoy Medical stock. DSG Capital Advisors LLC bought a new position in Envoy Medical, Inc. (NASDAQ:COCH) during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 625,000 shares of the company’s stock, valued at approximately $416,000. DSG Capital Advisors LLC owned about 0.81% of Envoy Medical as of its most recent SEC filing. Institutional investors own 8.59% of the company’s stock.

Envoy Medical Company Profile

Envoy Medical is a medical technology company focused on developing fully implanted hearing devices for people with sensorineural hearing loss. Unlike conventional hearing aids and many cochlear implants, its technology is designed to be placed beneath the skin, with no external wearable sound processor.

The company’s lead product is the Acclaim Cochlear Implant, a fully implanted cochlear implant intended to address moderate-to-profound sensorineural hearing loss in adults. The system is designed to use the body’s natural anatomy to capture sound and convert it into electrical signals that stimulate the auditory nerve.